SEC Tracker
Get the app

NRX Pharmaceuticals NRXP

NRX Pharmaceuticals reported a net loss of $28.62 million

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $28.62 million for the year ended Dec 31, 2025
  2. Annual meeting scheduled for Dec 17, 2026
  3. Dennis McBride to be elected as Board member

Written from the DEF 14A on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when NRX Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. iBio IBIO public float $58M, Dec 31, 2025
  2. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  3. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  4. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  5. Medicinova MNOV public float $62M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.